LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) today and set a price target of $10.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors surrounding Mereo Biopharma Group Plc’s promising developments. The company is advancing two critical Phase 3 studies for setrusumab, targeting osteogenesis imperfecta, with significant milestones expected by the end of 2025. These studies, which include a placebo-controlled trial and a head-to-head comparison with bisphosphonates, are pivotal for evaluating the drug’s efficacy in reducing fracture rates.
Furthermore, Mereo’s financial position appears robust, with sufficient cash reserves projected to last until 2027, potentially extending beyond the approval of setrusumab, contingent on positive clinical outcomes. The upcoming interim analysis for the Orbit trial is anticipated to be a significant event for the stock, with expectations bolstered by the inclusion of a higher proportion of patients with more severe forms of the condition, which could enhance the probability of success. These factors collectively underpin the optimistic outlook and the Buy rating assigned by Cory Jubinville, PhD.
In another report released today, Needham also maintained a Buy rating on the stock with a $7.00 price target.